``Two leading bioinformaticists have issued a call to arms to their colleagues in response to Science's decision to allow Celera to submit its genome data under special circumstances. `Agitate. Let Science know you care,' write the letter's authors, Ewan Birney of the European Bioinformatics Institute and Sean Eddy of the Howard Hughes Medical Institute and Washington University. `Even if we can't change the deal with Celera, we can try to make sure it's a one-time only deal that's viewed as a Big Mistake.' Under the terms of the agreement, which the parties announced Thursday, Science has agreed to allow Celera to submit its human genome sequence data to the journal while making the data available only on its website, not through a public international database such as Genbank, EMBL, or DDBJ. Previously, researchers have had to submit gene data to a public database before publication in Science.''
Hi,
I would be more interested in finding out about
market potential for bioinformatics systems for
drug discovery. Do you have any leads from where
I could get more information on the total market
for this? What is your source for teh market
data you have posted?
Thanks.
![[I, Librarian]](https://www.bioinformatics.org/images/ack_banners/ILibrarian-728x90.png)
![[Photo]](https://www.bioinformatics.org/images/photo.php?photo_id=4)
